NCT06113445: An ongoing trial by Incyte Corporation
This trial is ongoing. It must report results 1 year, 2 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06113445 |
|---|---|
| Title | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Nov. 29, 2023 |
| Completion date | Feb. 25, 2026 |
| Required reporting date | Feb. 25, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |